Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
188Re-PTI-6D2 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 188Re-PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Histologically confirmed Stage IIIc (unresectable) or Stage IV metastatic melanoma; * measurable disease; * at least 18 years of age; * Karnofsky status at least 50%; * life expectancy \> 3 months; * at least 4 weeks since prior therapy; * adequate organ and marrow function de...
Top 20 of 52 competitors
188Re-PTI-6D2 is an investigational small molecule therapeutic being developed by Filana Therapeutics, Inc. for metastatic melanoma. It is a Phase 1-stage oncology asset that has been studied in a single completed clinical trial. It is not an approved product and remains in clinical development.
188Re-PTI-6D2 was studied as a treatment for patients with metastatic melanoma, an advanced form of skin cancer that has spread beyond the original site. The only clinical trial of this agent enrolled adults 18 years and older with metastatic melanoma. It is investigational and has not been approved for any use.
188Re-PTI-6D2 is being developed by Filana Therapeutics, Inc., which trades under the ticker FLNA. Filana Therapeutics is the sponsor of the clinical program for this metastatic melanoma candidate. No other developer or partner is associated with the asset based on its public development record.
188Re-PTI-6D2 is in Phase 1 development. Its single clinical trial, NCT00399113, was a Phase 1 safety study in metastatic melanoma and is now completed. The program has no active trials, and the drug is investigational rather than approved.
188Re-PTI-6D2 has been evaluated in one clinical trial, NCT00399113, titled Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma. That Phase 1 trial was completed and enrolled 12 participants in Israel. It was an uncontrolled study open to all sexes, with no healthy volunteers.
188Re-PTI-6D2 is not approved. It is an investigational agent that has completed a single Phase 1 safety trial in metastatic melanoma, and no regulatory approval has been granted for this candidate. Further clinical development would be required before any approval could be considered.